Have you checked out our newsletter?
Stay ahead with expert insights, strategic tips, and industry trends—all designed to boost your brand's med comm initiatives.
"*" indicates required fields
Get fresh insights and candid perspectives on timely issues impacting the pharmaceutical industry from our blog.
The Latest News
Will Your Launch Strategy Succeed or Fail?
The Challenge: A Faster, More Complex Launch Environment In today’s pharmaceutical market, strong science is the foundation, but it doesn’t always guarantee a successful launch. Many of us have experienced a disappointing launch when everything we anticipated pointed to success. Today, launches are more complex than they were a decade
Industry Insights – June 2026
From evolving China deal dynamics and prolonged job searches to the growing push for AI-driven drug repurposing, explore how shifts in BioPharma are redefining innovation, hiring, and strategy across the sector. Don’t miss the latest: Source: PharmaVoice The FDA is ramping up efforts to identify new uses for existing drugs,
Industry Insights – May 2026
Biosimilars are gaining U.S. momentum even as patent thickets keep triggering legal fights, small biotechs are feeling the pressure of the FDA’s faster-moving approval environment, and the agency is testing real-time clinical trial review with big-name drugmakers already on board. It’s a fast-changing drug-development landscape worth watching. Don’t miss the
Virtual Speaker Programs for Busy Providers
The Biggest Challenge Is Not Lack of Information In the current healthcare environment, new drugs are being approved by the FDA daily. Imagine a healthcare provider who sees a patient recently diagnosed with obesity and is looking to start a weight-loss program. The physician has a busy practice. She often finds it time-consuming
BioPharma in the News – April 2026
The FDA is escalating its ongoing push for transparency and tougher enforcement, including publicizing complete response letters, seeking new authority over DTC drug advertising, and tightening expectations around external controls in rare disease trials. Don’t miss the latest in the industry. Source: PharmaVoice The FDA’s push for “radical transparency” is
When the Universe Has Other Plans: How to Save a Speaker Program in Crisis
It’s the perfect storm: TSA staffing shortages, extreme weather, constant flight delays, and airlines cutting hundreds of flights daily1. There is an in-person speaker program tonight. Your scheduled speaker wakes up to a ping on his phone at 4:30 am and finds the dreaded message: “We have been notified by
What’s Trending in BioPharma – March 2026
Europe risks falling behind in the global BioPharma race, the FDA is working to increase accessibility to personalized treatments in rare diseases, and regulators are cracking down on unapproved compounded GLP-1 weight loss drugs. Together, these three stories show the shifting landscape of innovation, regulation, and competition shaping the BioPharma
What’s Trending in BioPharma – February 2026
The BioPharma industry is in rapid flux, shaped by transforming drug pipelines, the ongoing political battle over lowering drug prices, and a new rebate model for the 340B Drug Discount program. Here’s what’s shaping the latest in healthcare. Source: BioPharma International In a recent BioPharm International interview, Janice MacLennan, founder
Launch Broadcast? Yes! Mid Product Life-Cycle? ABSOLUTELY!
One of the most persistent myths about broadcasts is that they are only good for new product launches. The reality is that while product launches are indeed a great time to deploy wide-reaching national broadcasts, their utility extends far beyond this single use. National broadcasts are perfect for announcing newly